BTAI INVESTOR DEADLINE: BioXcel Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, July 15, 2023 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of BioXcel Therapeutics, Inc. (NASDAQ: BTAI) securities between December 15, 2021 and June 28, 2023, both dates inclusive (the “Class Period”) have until September 5, 2023 to…